Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00990587 |
Recruitment Status
:
Completed
First Posted
: October 7, 2009
Last Update Posted
: June 22, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is an open-label, single arm study. Approximately 3-30 patients will be enrolled. Patients will receive Oral ciclopirox olamine (aqueous suspension), initial starting dose of 5 mg/m2/day administered as a single dose daily for 5 days. Three patients will initially be treated at each dose level in sequential cohorts. Dose escalation will continue for each subsequent cohort based on toxicity and plasma drug concentrations observed during the previous cohort. Dose escalation will continue until establishment of the maximum tolerated dose (MTD) has been met.
Patients who have demonstrated response to treatment, up to 6 total cycles of treatment may be administered. If additional cycles are warranted, ciclopirox olamine will be given at the same dose and frequency as the patient initially received.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hematologic Malignancy Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Hodgkin's Disease | Drug: Ciclopirox Olamine | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | May 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Ciclopirox Olamine
Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
|
Drug: Ciclopirox Olamine
Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
|
- To evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of ciclopirox olamine. [ Time Frame: 2 years ]
- To evaluate maximum tolerated dose. [ Time Frame: 2 years ]
- To evaluate recommended phase II dose of ciclopirox olamine. [ Time Frame: 2 years ]
- To determine the pharmacodynamic effects of ciclopirox olamine on survivin expression, and relate to the steady-state plasma concentrations of ciclopirox olamine. [ Time Frame: 2 years ]
- To determine the response rate of ciclopirox olamine. [ Time Frame: 2 years ]
- To characterize the pharmacokinetics (PK) of ciclopirox olamine in patients with relapsed or refractory hematologic malignancy. [ Time Frame: 2 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 18
- Relapsed or refractory hematologic malignancies including AML, ALL, CLL, high risk myelodysplasia (International Prognostic Score >2.5), CML blast crisis, multiple myeloma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma for which all potentially curative therapy options have been exhausted.
- ECOG (Eastern Cooperative Oncology Group) performance status < 2.
-
Biochemical values within the following range:
- Serum creatinine < 2x upper limit of normal.
- Total bilirubin < 2x upper limit of normal, AST (asparatate aminotransferase) and ALT (alanine aminotransferase) < 5x upper limit of normal.
- Ability to maintain adequate oral intake of medication.
- Ability to understand and sign informed consent.
- Toxicity from prior chemotherapy has resolved
Exclusion Criteria:
- Uncontrolled systemic infection.
- Uncontrolled intercurrent illness
- Pregnant or breast feeding
- Active CNS (central nervous system) disease
- Neurologic symptoms related to intracurrent illnesses or unexplained causes
- Psychiatric illness that would limit compliance with study
- Receiving other systemic chemotherapy, other than hydroxyurea to control circulating blast counts, within 10 days of study entry. Hydroxyurea is permitted, however the dose must be stable and unchanged in the 7 days prior to initiation with ciclopirox olamine
- Concurrent therapy with topical ciclopirox olamine.
- Use of other investigational anti-cancer therapy within two weeks of study entry.
- Use of oral or intravenous metal supplements including iron, copper, zinc and nickel.
- Resting ejection fraction < 50%

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00990587
Canada, British Columbia | |
Vancouver General Hospital | |
Vancouver, British Columbia, Canada, V5Z 1M9 | |
Canada, Ontario | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 |
Principal Investigator: | Mark Minden, MD | Princess Margaret Hospital, Canada |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT00990587 History of Changes |
Other Study ID Numbers: |
CPX V001 |
First Posted: | October 7, 2009 Key Record Dates |
Last Update Posted: | June 22, 2015 |
Last Verified: | June 2015 |
Keywords provided by University Health Network, Toronto:
relapsed and refractory hematologic malignancy ALL (acute lymphoid leukemia) CLL (chronic lymphoid leukemia) |
High risk myelodysplasia (MDS) with an IPSS (International Prognostic Scoring System) score >2.5 CML (chronic myelogenous leukemia) blast crisis Relapsed or refractory acute myeloid leukemia (AML) |
Additional relevant MeSH terms:
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive Hodgkin Disease Precursor Cell Lymphoblastic Leukemia-Lymphoma Myelodysplastic Syndromes Preleukemia Neoplasms by Histologic Type Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell Myeloproliferative Disorders Bone Marrow Diseases Hematologic Diseases Lymphoma Precancerous Conditions Ciclopirox Antifungal Agents Anti-Infective Agents |